Thrombotic Thrombocytopenic Purpura and Gemcitabine (original) (raw)

Gemcitabine-associated thrombotic thrombocytopenic purpura

Farheen Shah-Khan

The Lancet Oncology, 2007

View PDFchevron_right

The cumulative incidence of gemcitabine-induced thrombotic microangiopathy

JÓn Hrafnkelsson

Acta Oncologica, 2007

View PDFchevron_right

Management of thrombotic thrombocytopenic purpura: current perspectives

tiffany patrick

Journal of Blood Medicine, 2014

View PDFchevron_right

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura

Aikaterini Bitsani

New England Journal of Medicine, 2016

View PDFchevron_right

George JN. How I treat patients with thrombotic thrombocytopenic purpura: Blood. 2010;116(20):4060-4069

Paula Roca

Blood, 2011

View PDFchevron_right

Two Mechanistic Pathways for Thienopyridine-Associated Thrombotic Thrombocytopenic Purpura

Joseph Kiss, Ravindra Sarode

Journal of the American College of Cardiology, 2007

View PDFchevron_right

Gemcitabine-induced thrombotic microangiopathy: a systematic review

Edward Bourry

View PDFchevron_right

Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report

Marina Noris

Blood, 2005

View PDFchevron_right

Recent advances in thrombotic thrombocytopenic purpura

Toshiyuki Miyata

Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2004

View PDFchevron_right

Updates on thrombotic thrombocytopenic purpura: Recent developments in pathogenesis, treatment and survivorship

Eleni Gavriilaki

Thrombosis Update, 2021

View PDFchevron_right

Rituximab in patients with refractory thrombotic thrombocytopenic purpura

S. Salah

Journal of Thrombosis and Haemostasis, 2004

View PDFchevron_right

Drug-induced Thrombotic Microangiopathy Caused by Gemcitabine

Huda Naim

Cureus, 2018

View PDFchevron_right

Thrombotic microangiopathy and digital necrosis: two unrecognized toxicities of gemcitabine

Heang Ly

Anti-Cancer Drugs, 2003

View PDFchevron_right

Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura

Anja Mühlfeld

Blood Advances, 2020

View PDFchevron_right

Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura

laura sargentini

Expert Review of Clinical Pharmacology

View PDFchevron_right

Vincristine as an Adjunct to Therapeutic Plasma Exchange for Thrombotic Thrombocytopenic Purpura: A Single Institution Experience

Teoman Soysal

Balkan medical journal, 2018

View PDFchevron_right

Gemcitabine-associated thrombotic microangiopathy

Jeff Sharman

Cancer, 2004

View PDFchevron_right

Treatment of thrombotic thrombocytopenic purpura

Johanna Kremer

Intensive Care Medicine, 2005

View PDFchevron_right

Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis

Johanna Kremer

Blood Advances, 2021

View PDFchevron_right

Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura

Johanna Kremer

American Journal of Hematology, 2012

View PDFchevron_right

Approach to Management of Thrombotic Thrombocytopenic Purpura at University of Cincinnati

Ronald Sacher

Advances in Hematology, 2013

View PDFchevron_right

Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature

Ravindra Sarode

British Journal of Haematology, 2004

View PDFchevron_right

Gemcitabine-associated thrombotic microangiopathy – a role for eculizumab?

Teresa Chuva

Portuguese Journal of Nephrology & Hypertension, 2020

View PDFchevron_right

The role of pulse dexamethasone in acquired idiopathic thrombotic thrombocytopenic purpura

Ponlapat Rojnuckarin

Journal of Thrombosis and Haemostasis, 2006

View PDFchevron_right